Wilms Tumor with Lymph Node Involvement is Stage III
A Wilms tumor with regional lymph node involvement is classified as Stage III disease. 1, 2
Staging Criteria for Stage III Wilms Tumor
Stage III designation in Wilms tumor is determined by four pathologic criteria 2:
- Positive regional lymph nodes (most common criterion, accounting for 38% of Stage III cases) 2
- Peritoneal implants 2
- Microscopic or gross residual disease 2
- Tumor rupture or spillage 2
Lymph node involvement alone is the single most frequent criterion for Stage III designation, and notably, 41% of all Stage III cases are designated Stage III solely on the basis of positive lymph nodes. 3
Critical Importance of Lymph Node Sampling
Failure to perform adequate lymph node sampling represents a significant protocol violation that can lead to understaging and inadequate treatment. 3, 4
- Lymph node sampling was not performed in 9% of nephrectomies in NWTS-5, including 4% of Stage III cases 3
- Absence of lymph node biopsy is associated with increased relative risk of local recurrence, with the largest risk observed in children with Stage I disease 4
- In Stage II patients where lymph nodes were not sampled, there is an increased local relapse rate 3
- Regional lymph nodes (stations 1-12 and 14v for gastric tumors) must be adequately assessed for accurate staging 5
Prognostic Implications
Lymph node positivity is a highly adverse prognostic factor that significantly impacts survival outcomes. 1, 2
- Multivariate analysis demonstrates that lymph node involvement has a relative risk of 1.89 (p=0.005) for event-free survival 2
- The prognostic impact is amplified when combined with loss of heterozygosity (LOH) of 1p or 16q 1
- Patients with both positive lymph nodes and LOH have the worst event-free survival (hazard ratio 6.33) 1
- Patients with positive nodes but negative LOH have significantly worse event-free survival (hazard ratio 3.57) compared to those with both negative 1
Treatment Implications
Stage III favorable histology Wilms tumor with lymph node involvement requires intensified therapy with vincristine/dactinomycin/doxorubicin (DD4A) plus radiation therapy. 1, 2
- The 8-year event-free survival for all patients with local Stage III favorable histology Wilms tumor is 82%, with overall survival of 91% 2
- Patients with lymph node positivity combined with singular LOH 1p or 16q may require further intensified therapy in future prospective clinical trials 1
- Survival after local recurrence is poor (43% at 2 years), emphasizing the importance of accurate initial staging and appropriate treatment intensity 4